HEC Pharma Co. Ltd. recently presented HEC-201625, a small-molecule PD-L1 inhibitor for cancer immunotherapy that blocks the PD-1/PD-L1 signaling pathway. HEC-201625 was tested in vitro and in vivo in MC38 syngeneic murine model, as well as in xenograft A375 and NCI-H358 models.
Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.
The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.
Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.
Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.
Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.
Tumors with strong immunosuppressive microenvironments such as microsatellite-stable colorectal cancer (MSS-CRC) remain unresponsive to immune checkpoint blockade therapy, with <20% of gastrointestinal tumors responding to therapy.
Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor (ARON) degrader, in models of prostate cancer.
RSS
